EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly

Ashok A Ganeshalingam iD, Nicolai Uhrenholt, Sidse Arnfred, Peter Gæde, Andreas K Pedersen, Niels Bilenberg, Jan Frystyk

Diabetes Care · 2026

DOI: 10.2337/dc25-2041 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2026. Verfasst von Ashok A Ganeshalingam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Research Unit, Department of Endocrinology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Insulin Resistance, Insulin-Secreting Cells, Antipsychotic Agents, Schizophrenia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Region Sjælland, Steno Diabetes Center Zealand, Aase og Ejnar Danielsens Fond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To examine the effects of semaglutide on insulin sensitivity, insulin resistance, and β-cell function and explore whether these changes were mediated by weight loss in overweight or obese individuals with schizophrenia and prediabetes receiving second-generation antipsychotics. RESEARCH DESIGN AND METHODS In this 30-week, double-blind trial, 154 participants were randomized to semaglutide (n = 77) or placebo (n = 77); 141 (91.5%) completed the study. Baseline and end-of-study assessments included fasting glucose, insulin, C-peptide, HOMA2 of β-cell function, HOMA2 of insulin sensitivity, HOMA of insulin resistance, and body weight. RESULTS Participants (56% women, mean age 38.3 years) provided complete insulin data in 131 cases. Compared with placebo, semaglutide significantly reduced fasting glucose (−0.87 mmol/L [95% CI −1.15, −0.59]; P < 0.001), improved insulin sensitivity (8.60 [5.82, 13.65]; P = 0.001), and lowered insulin resistance (−0.69 [−1.00, −0.20]; P = 0.006). Mean weight loss was 9.2 kg and mediated improvements in insulin sensitivity (estimate 7.82; P = 0.01) and insulin resistance (estimate −0.75; P = 0.01). Nonsignificant trends were observed toward reduced fasting insulin (−52.3 pmol/L; P = 0.11) and C-peptide (−182.9 pmol/L; P = 0.096), with a modest, nonsignificant increase in β-cell function (8.10; P = 0.19). CONCLUSIONS Semaglutide significantly improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and promoted substantial weight loss in patients with antipsychotic-induced metabolic disturbances. Weight loss partly mediated the metabolic improvements, while β-cell function remained largely unchanged. These findings support semaglutide as a potential strategy for mitigating metabolic dysfunction in this high-risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistanceInsulin-Secreting CellsAntipsychotic AgentsSchizophreniaObesityGlucagon-Like PeptidesPrediabetic StateHumansSemaglutideFemaleAdultMaleMiddle AgedDouble-Blind MethodBlood GlucoseInsulinC-Peptide

Substanzen

SemaglutideAntipsychotic AgentsGlucagon-Like PeptidesBlood GlucoseInsulinC-Peptide

Autor:innen und Institutionen

  • Endocrine Research Unit, Department of Endocrinology, Odense University Hospital, Odense, Denmark.
  • Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Odense, Denmark.
  • Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.
  • Research Unit for Clinical Psychopharmacology, Psychiatry West in Region Zealand, Slagelse, Denmark.
  • Child and Adolescent Psychiatry Odense, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.
  • Psychiatric Research Unit, Copenhagen University Hospital-Psychiatry Region Zealand, Slagelse, Denmark.

ORCID-Profile: Ashok A Ganeshalingam

Förderung

  • Region Sjælland
  • Steno Diabetes Center Zealand
  • Aase og Ejnar Danielsens Fond
  • Novo Nordisk Fonden
  • Steno Diabetes Center Odense

Zitieren

APA

Ganeshalingam, A. A., Uhrenholt, N., Arnfred, S., Gæde, P., Pedersen, A. K., Bilenberg, N., & Frystyk, J. (2026). Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. Diabetes Care. https://doi.org/10.2337/dc25-2041

Vancouver

Ganeshalingam AA, Uhrenholt N, Arnfred S, Gæde P, Pedersen AK, Bilenberg N, et al. Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. Diabetes Care. 2026. doi:10.2337/dc25-2041

BibTeX
@article{Ganeshalingam2026,
  author = {Ganeshalingam, Ashok A and Uhrenholt, Nicolai and Arnfred, Sidse and Gæde, Peter and Pedersen, Andreas K and Bilenberg, Niels and Frystyk, Jan},
  title = {Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly},
  journal = {Diabetes Care},
  year = {2026},
  doi = {10.2337/dc25-2041}
}
Kostenlos starten →